HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS
LATEST UPDATES » Vol 23, No 08, August 2019 – Digitalization vs Digitization — Exploring Emerging Trends in Healthcare       » Shanghai neurologists test brain implant to tackle drug addiction       » Gene-editing researchers reduce cancer risk       » Artificial Intelligence in Precision Cancer Diagnostics: Myth or Magic?       » Healing with Technology       » Smart Hospital: An Instrument of Care       » Transforming Healthcare with Data and Artificial Intelligence      
EYE ON CHINA
Better treatment for liver transplant rejection
Tacrolimus drug encapsulated in hydrogels had a better inhibition effect on the activated T-cells than direct oral administration of tacrolimus

Chinese scientists have potentially found a more effective solution to liver transplant rejection, which is life-threatening when it occurs.

Liang Gaolin, head of a research team at the University of Science and Technology of China, has developed a new treatment for liver transplant rejection in collaboration with two other teams led by Wang Xuehao and Wang Fuqiang from Nanjing Medical University.

The findings, which were published in the latest issue of Advanced Materials, have been proven effective in rats, but are yet to be tested in clinical trials.

Rejection is the biggest problem of organ transplants. Immune suppressive drugs such as tacrolimus are directly administered to patients after their surgery for T-cell inhibition. However, direct oral administration of tacrolimus can result in severe side effects.

Cell experiments on rats have shown that tacrolimus encapsulated in two hydrogels when applied to the scar surface of the transplant has a better inhibition effect on the activated T-cells than free drug tacrolimus.

Liver transplant experiments indicate that, with the same dose of tacrolimus, rat recipients in the gel group showed a significantly extended median survival time of 22 days, while the rats treated with conventional tacrolimus medication only had a median survival time of 13 days.

The researchers expect to bring this "smart" facile method of tacrolimus immune responsive release into clinical trial phase in the near future.

Source: Xinhua

Click here for the complete issue.

NEWS CRUNCH  
news How blockchain can save the food industry millions from recalls
news China Healthcare and Pharma Digital Innovation Summit
news BIO-PHARM2019 — The Most Influential Forum in China's Biopharm Industry
news The rise of personalised nutrition
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  
SPOTLIGHT  
LIFE OF A SCIENTIST  

APBN Editorial Calendar 2019
January:
Taiwan Medical tourism
February:
Marijuana as medicine — Legal marijuana will open up scientific research
March:
Driven by curiosity
April:
Career developments for researchers
May:
What's cracking — Antibodies in ostrich eggs
June:
Clinical trials — What's in a name?
July:
Traditional Chinese medicine in modern healthcare — Integrating both worlds
Editorial calendar is subjected to changes.
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Deborah Seah
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com
Copyright© 2019 World Scientific Publishing Co Pte Ltd  •  Privacy Policy